Jazz Pharmaceuticals (JAZZ) Stock Highlights

119.24 | +2.07%

2024-11-21 01:13:30

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Statistics

Range Today

116.43 119.47

Volume Today 401.63K

Range 1 Year

99.06 134.17

Volume 1 Year 170.05M

Range 3 Year

99.06 169.98

Volume 3 Year 451.88M

Range 10 Year

86.88 194.73

Volume 10 Year 1.52B

Highlights

Market Capitalization 7.47B (mid)

Floating Shares 59.64M

Current Price 119.24

Price To Earnings 16.17

Price To Revenue 2.79

Price To Book 1.82

Earnings Per Share 7.33

Payout Ratio 0%

Performance

Latest +2.07%

1 Month +3.69%

3 Months +4.38%

6 Months +8.85%

1 Year -0.7%

3 Years -7.68%

5 Years -13.84%

10 Years -30.21%

Benchmarks

Market Capitalization

22 / 368

Gross Profits

5 / 278

Total Revenue

4 / 300

Total Rank

29 / 368

Free Cashflow

3 / 352

Performance 5 years

135 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.